According to PRNews
In the clinical trial supporting this approval, patients with schizophrenia who were treated with SEROQUEL XR experienced a significantly longer time to relapse, compared with patients receiving placebo. Patients receiving SEROQUEL XR demonstrated an 84% reduction in the relative risk of relapse (hazard ratio 0.16; p<0.0001). Results showed the estimated risk of relapse after six months was 14.3% in the SEROQUEL XR group versus 68.2% in the placebo group (p<0.0001). Differences in relapse rate between active treatment and placebo were large enough to require the study to be stopped early. The complete results of the clinical trial appear in the November issue of the journal Psychiatry 2007.
"Today's FDA approval helps address the need for longer-term treatment options for patients with schizophrenia," said Mark Scott, Ph.D., Executive Director for Development, AstraZeneca. "The clinical trial results provided compelling evidence for reducing the risk of relapse when these patients are treated with SEROQUEL XR."
.jpg)
» Stock Market Fluctuations in Big Pharmas as of February 8, 2008 from PharmaGazette
Company Name, Symbol, Share Price, ChangeAbbott Laboratories' (NYSE:ABT) - $56.80 -1.30 (-2.24%) AstraZeneca (NYSE:AZN) - $37.96 -0.76 (-1.96%) Bristol-Myers Squibb (NYSE:BMY) - $23.07 -0.27 (-1.16%) Eli Lilly & Co. (NYSE:LL... [Read More]
Tracked on: February 8, 2008 3:41 PM | Permalink to Trackback